<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-956
Date of Submission: 2025-06-08

This report was submitted by a Other Healthcare Professional from Jackson and Sons Medical Center concerning patient ANON-PX-6143. The subject is a 24-year-old other with a significant medical history including osteoarthritis, hypertension, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Metformin administered via the Intramuscular route at a dosage of 208mg, initiated on 2025-04-20 for Type 2 diabetes and discontinued on 2025-05-21; Omeprazole (Proton-pump inhibitor) administered via the Oral route at a dosage of 172mg, initiated on 2025-04-20 for Gastroesophageal reflux disease and discontinued on 2025-05-21.

On approximately 2025-05-13, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Nausea, Maculopapular Rash. The Nausea was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovering'. The Maculopapular Rash was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Positive dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

</data>
report_id: ADR-2025-956
report_date: '2025-06-08'
patient_details:
  patient_id: ANON-PX-6143
  gender: Other
  relevant_history:
  - osteoarthritis
  - hypertension
  - chronic kidney disease
  age_at_reaction: 24
suspected_drugs:
- drug_name: Metformin
  dosage: 208mg
  route_of_administration: Intramuscular
  start_date: '2025-04-20'
  indication_for_use: Type 2 diabetes
  end_date: '2025-05-21'
- drug_name: Omeprazole
  dosage: 172mg
  route_of_administration: Oral
  start_date: '2025-04-20'
  indication_for_use: Gastroesophageal reflux disease
  drug_class: Proton-pump inhibitor
  end_date: '2025-05-21'
adverse_reactions:
- symptom_name: Nausea
  onset_date: '2025-05-13'
  severity: Life-threatening
  outcome: Recovering
  intervention_required: true
- symptom_name: Maculopapular Rash
  onset_date: '2025-05-13'
  severity: Life-threatening
  outcome: Fatal
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Positive dechallenge
reporting_facility: Jackson and Sons Medical Center
reporter_type: Other Healthcare Professional
